The estimated Net Worth of Guy Macdonald is at least $4.17 Milhão dollars as of 21 December 2020. Mr. Macdonald owns over 8,000 units of Scynexis Inc stock worth over $16,800 and over the last 11 years he sold SCYX stock worth over $4,157,861. In addition, he makes $0 as Director at Scynexis Inc.
Sign up
Mr. Macdonald SCYX stock SEC Form 4 insiders trading
Guy has made over 34 trades of the Scynexis Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he bought 8,000 units of SCYX stock worth $50,000 on 21 December 2020.
The largest trade he's ever made was buying 40,000 units of Scynexis Inc stock on 24 June 2016 worth over $95,600. On average, Guy trades about 8,061 units every 34 days since 2013. As of 21 December 2020 he still owns at least 12,000 units of Scynexis Inc stock.
You can see the complete history of Mr. Macdonald stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Guy Macdonald biography
Guy Macdonald is directors of the Company since November 2014. He has served as the President and Chief Executive Officer and a member of the board of directors of Tetraphase Pharmaceuticals, Inc. since January 2008. From August 2003 until January 2008, Mr. Macdonald served as Executive Vice President of Operations of Idenix Pharmaceuticals, Inc., a biopharmaceutical company. From 1981 to 2003 he served in various positions at Merck & Co., Inc., most recently serving as the Vice President for Anti-Infective and Hospital Products. In addition to his role on the Board of
How old is Guy Macdonald?
Guy Macdonald is 60, he's been the Director of Scynexis Inc since 2014. There are 7 older and 7 younger executives at Scynexis Inc. The oldest executive at Scynexis Inc is Patrick Langlois, 70, who is the Director.
What's Guy Macdonald's mailing address?
Guy's mailing address filed with the SEC is 1 EVERTRUST PLAZA, 13TH FLOOR, JERSEY CITY, NJ, 07302-6548.
Insiders trading at Scynexis Inc
Over the last 10 years, insiders at Scynexis Inc have traded over $4,708,140 worth of Scynexis Inc stock and bought 2,173,590 units worth $13,469,713 . The most active insiders traders include Advisors Llcperceptive Life..., Patrick Machado, eMarco Taglietti. On average, Scynexis Inc executives and independent directors trade stock every 49 days with the average trade being worth of $64,694. The most recent stock trade was executed by Marco Taglietti on 26 April 2022, trading 75,000 units of SCYX stock currently worth $225,000.
What does Scynexis Inc do?
scynexis, inc. is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. our scientists have extensive experience in the life sciences industry having, together and individually, been involved in the discovery and development of innovative medicines over a broad range of therapy areas. we are developing our lead product candidate, scy-078, a novel antifungal in phase 2, as a novel oral and intravenous drug for the treatment of serious and life-threatening invasive fungal infections in humans.
What does Scynexis Inc's logo look like?
Complete history of Mr. Macdonald stock trades at Scynexis Inc e Tetraphase Pharmaceuticals
Scynexis Inc executives and stock owners
Scynexis Inc executives and other stock owners filed with the SEC include:
-
Dr. Marco Taglietti M.D.,
CEO, Pres & Director -
Dr. Marco Taglietti,
CEO, Pres & Director -
David Gonzalez Angulo,
Chief Medical Officer -
Eric Francois,
Chief Financial Officer -
Christine R. Coyne M.B.A.,
Chief Commercial Officer -
Philippe Tinmouth,
Director -
Jean-Yves Nothias,
Director -
Guy Macdonald,
Director -
Patrick Langlois,
Director -
David Hastings,
Director -
Ann Hanham,
Director -
Steven Gilman,
Director -
Laurent Arthaud,
Director -
Armando Anido,
Director -
David Angulo,
Chief Medical Officer -
Scott Sukenick,
General Counsel -
Nkechi Azie,
Vice President - Clinical Development -
Jim Maffezzoli,
Vice President of Sales and Marketing -
Eric Francois,
Chief Financial Officer -
Marco Taglietti,
President, Chief Executive Officer, Director -
Pamela Kirby,
Chairman of the Board -
Debbie Etchison,
Exec. Director of Communications -
Lawrence R. Hoffman CPA, Esq.,
Interim CFO & Principal Accounting Officer -
Dr. Rajeshwar Motheram,
Sr. VP of Pharmaceutical Devel. & Supply Chain -
Scott Sukenick J.D.,
Gen. Counsel & Corp. Sec. -
Patrick Machado,
Director -
Marion Mc Court,
Director -
Jr. Charles F Osborne,,
Chief Financial Officer -
Biopharma Partners Ii Lpalt...,
-
Carole Sable,
Chief Medical Officer -
Capital Ii Ventech,
10% owner -
Biotechnology Fund Fcpr,
10% owner -
Eileen Pruette,
General Counsel -
Genavent F.C.P.R.,
10% owner -
Mounia Chaoui,
Director -
Edward Penhoet,
Director -
Yves J Ribeill,
President and CEO -
Advisors Llcperceptive Life...,
-
Christine Coyne,
Chief Commercial Officer -
Ivor Macleod,
Chief Financial Officer